Quantitative Transport Mapping and Radio-genomics Model in Predicting Tumor Response of Neoadjuvant Therapy in Breast Cancer

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100047918

Enrollment

Unknown

Registered

2021-06-27

Start date

2021-06-28

Completion date

Unknown

Last updated

2022-03-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Interventions

case series:none

Eligibility

Sex/Gender

Female

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Invasive ductal carcinoma was confirmed by hollow needle puncture in our hospital; 2. No drug and/or surgical treatment before enrollment; 3. It is planned to perform neoadjuvant therapy for more than 4 cycles in our hospital.

Exclusion criteria

Exclusion criteria: 1. General contraindications of MR examination (contrast agent allergy, implanted cardiac pacemaker, cochlear implant, claustrophobia, etc.); 2. Patients with other malignant tumors or distant metastasis; 3. The patient has not completed complete NAT treatment or has not undergone surgical resection after NAT.

Design outcomes

Primary

Measure	Time frame
Kinetic features;	—

Countries

China

Contacts

Public ContactYang Fan

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

fyang@vip.163.com+86 13871266365

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026